Search Results - "JUDSON, Patricia L"

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer by AGHAJANIAN, Carol, BLANK, Stephanie V, GOFF, Barbara A, JUDSON, Patricia L, TENERIELLO, Michael G, HUSAIN, Amreen, SOVAK, Mika A, JING YI, NYCUM, Lawrence R

“…This randomized, multicenter, blinded, placebo-controlled phase III trial tested the efficacy and safety of bevacizumab (BV) with gemcitabine and carboplatin…”
Get full text

Lymphatic Mapping and Sentinel Lymph Node Biopsy in Women With Squamous Cell Carcinoma of the Vulva: A Gynecologic Oncology Group Study by LEVENBACK, Charles F, ALI, Shamshad, LEITAO, Mario M, BAKKUM-GAMEZ, Jamie N, ROSSI, Emma C, LENTZ, Samuel S, BURKE, James J, VAN LE, Linda, TRIMBLE, Cornelia L, COLEMAN, Robert L, GOLD, Michael A, FOWLER, Jeffrey M, JUDSON, Patricia L, BELL, Maria C, DE GEEST, Koen, SPIRTOS, Nick M, POTKUL, Ronald K

“…To determine the safety of sentinel lymph node biopsy as a replacement for inguinal femoral lymphadenectomy in selected women with vulvar cancer. Eligible…”
Get full text

Trends in the incidence of invasive and in situ vulvar carcinoma by JUDSON, Patricia L, HABERMANN, Elizabeth B, BAXTER, Nancy N, DURHAM, Sara B, VIRNIG, Beth A

“…To characterize the incidence of vulvar carcinoma in situ and vulvar cancer over time. We used the Surveillance Epidemiology and End Results database to assess…”
Get full text

Complementary and Alternative Medicine Use in Individuals Presenting for Care at a Comprehensive Cancer Center by Judson, Patricia L., Abdallah, Reem, Xiong, Yin, Ebbert, Judith, Lancaster, Johnathan M.

“…Purpose: To define the use of complementary and alternative medicine (CAM) in individuals presenting for care at a comprehensive cancer center. Patients and…”
Get full text

Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173 by Coleman, Robert L, Ali, Shamshad, Levenback, Charles F, Gold, Michael A, Fowler, Jeffrey M, Judson, Patricia L, Bell, Maria C, De Geest, Koen, Spirtos, Nick M, Potkul, Ronald K, Leitao, Mario M, Bakkum-Gamez, Jamie N, Rossi, Emma C, Lentz, Samuel S, Burke, James J, Van Le, Linda, Trimble, Cornelia L

“…Abstract Objective To determine which patients with near midline lesions may safely undergo unilateral groin dissection based on clinical exam and…”
Get full text

A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer by Argenta, Peter A, Thomas, Sajeena G, Judson, Patricia L, Downs, Levi S, Geller, Melissa A, Carson, Linda F, Jonson, Amy L, Ghebre, Rahel

“…Abstract Objective . The goal of treating recurrent ovarian cancer is disease control while minimizing toxicity. Fulvestrant, a novel estrogen receptor (ER)…”
Get full text

The Chinese herb polyphyllin D sensitizes ovarian cancer cells to cisplatin-induced growth arrest by Sawah, Entidhar Al, Marchion, Douglas C., Xiong, Yin, Ramirez, Ingrid J., Abbasi, Forough, Boac, Bernadette M., Bush, Stephen H., Zgheib, Nadim Bou, McClung, E. Clair, Khulpateea, Beman R., Berry, Amy, Hakam, Ardeshir, Wenham, Robert M., Lancaster, Johnathan M., Judson, Patricia L.

“…Purpose We evaluated the effects of polyphyllin D (PD), a natural compound with anti-neoplastic activity and a major component of the Chinese herb Paris…”
Get full text

Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers by Teefey, Patrick, MD, Zgheib, Nadim Bou, MD, Apte, Sachin M., MD, Gonzalez-Bosquet, Jesus, MD, PhD, Judson, Patricia L., MD, Roberts, William S., MD, Lancaster, Johnathan M., MD, PhD, Wenham, Robert M., MD

“…Objective We sought to evaluate the toxicity and tolerability of the intraperitoneal/intravenous regimen by comparing the modified regimen that is used at the…”
Get full text

Vulvar cancer in young women: demographic features and outcome evaluation by Lanneau, Grainger S., MD, Argenta, Peter A., MD, Lanneau, Marion S., MS, Riffenburgh, Robert H., PhD, Gold, Michael A., MD, McMeekin, D. Scott, MD, Webster, Nancy, MD, Judson, Patricia L., MD

“…Objective The objective of the study was to identify prognostic and environmental factors associated with vulvar carcinoma in young women. Study Design This…”
Get full text

Gene expression data reveal common pathways that characterize the unifocal nature of ovarian cancer by Marchion, Douglas C., PhD, Xiong, Yin, PhD, Chon, Hye Sook, MD, Al Sawah, Entidhar, MD, Bou Zgheib, Nadim, MD, Ramirez, Ingrid J., MD, Abbasi, Forough, BS, Stickles, Xiaomang B., MD, Judson, Patricia L., MD, Hakam, Ardeshir, MD, Gonzalez-Bosquet, Jesus, MD, PhD, Wenham, Robert M., MD, Apte, Sachin M., MD, Berglund, Anders E., PhD, Lancaster, Johnathan M., MD, PhD

“…Objective The objective of the study was to evaluate the biological validity of ovarian cancer (OVCA) screening and early detection efforts and to characterize…”
Get full text

Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest by Al Sawah, Entidhar, Chen, Xin, Marchion, Douglas C, Xiong, Yin, Ramirez, Ingrid J, Abbasi, Forough, Bou Zgheib, Nadim, Chon, Hye Sook, Wenham, Robert M, Apte, Sachin M, Judson, Patricia L, Lancaster, Johnathan M

“…Abstract Objectives AKT, a key regulator of diverse tumor signaling, is associated with progression of many cancers. Here, we investigated 1) the influence of…”
Get full text

Positron emission tomography and leiomyomas: Clinicopathologic analysis of 3 cases of PET scan-positive leiomyomas and literature review by Chura, Justin C, Truskinovsky, Alexander M, Judson, Patricia L, Johnson, Linda, Geller, Melissa A, Downs, Levi S

“…Abstract Introduction Studies have suggested that PET scans can differentiate between leiomyomas and leiomyosarcomas. Our experience, however, shows that PET…”
Get full text

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer by Geller, Melissa A, Cooley, Sarah, Judson, Patricia L, Ghebre, Rahel, Carson, Linda F, Argenta, Peter A, Jonson, Amy L, Panoskaltsis-Mortari, Angela, Curtsinger, Julie, McKenna, David, Dusenbery, Kathryn, Bliss, Robin, Downs, Levi S, Miller, Jeffrey S

“…Abstract Background Natural killer (NK) cells derived from patients with cancer exhibit diminished cytotoxicity compared with NK cells from healthy…”
Get full text

A prospective, randomized study analyzing sartorius transposition following inguinal–femoral lymphadenectomy by Judson, Patricia L., Jonson, Amy L., Paley, Pamela J., Bliss, Robin L., Murray, Karuna P., Downs, Levi S., Boente, Matthew P., Argenta, Peter A., Carson, Linda F.

“…Based on the reduced morbidity seen in our retrospective study, we undertook a prospective, randomized trial to determine whether transposition of the…”
Get full text

BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin by Bansal, Nisha, Marchion, Douglas C, Bicaku, Elona, Xiong, Yin, Chen, Ning, Stickles, Xiaomang B, Sawah, Entidhar Al, Wenham, Robert M, Apte, Sachin M, Gonzalez-Bosquet, Jesus, Judson, Patricia L, Hakam, Ardeshir, Lancaster, Johnathan M

“…The BCL2 family proteins are critical mediators of cellular apoptosis and, as such, have been implicated as determinants of cancer cell chemo-sensitivity…”
Get full text

Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer by Judson, Patricia L, Geller, Melissa A, Bliss, Robin L, Boente, Matthew P, Downs, Levi S, Argenta, Peter A, Carson, Linda F

“…Studies in several solid tumors have shown that the presence of occult metastasis in the bone marrow or peripheral blood is highly predictive of decreased…”
Get full text

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment by Akce, Mehmet, El-Khoueiry, Anthony, Piha-Paul, Sarina A., Bacque, Emeline, Pan, Peng, Zhang, Zhi-Yi, Ewesuedo, Reginald, Gupta, Divya, Tang, Yongqiang, Milton, Ashley, Zajic, Stefan, Judson, Patricia L., O’Bryant, Cindy L.

“…Purpose The purpose of this study is to characterize niraparib pharmacokinetics (PK) and safety in patients with normal hepatic function (NHF) versus moderate…”
Get full text

Complementary and Alternative Medicine Use in Women With Gynecologic Malignancy Presenting for Care at a Comprehensive Cancer Center by Abdallah, Reem, Xiong, Yin, Lancaster, Johnathan M, Judson, Patricia L

“…We evaluated complementary and alternative medicine (CAM) practices among women presenting to a National Cancer Institute-designated Comprehensive Cancer…”
Get more information

Bladder and bowel symptoms in cervical and endometrial cancer survivors by Donovan, Kristine A., Boyington, Alice R., Judson, Patricia L., Wyman, Jean F.

“…BackgroundPrevious studies likely underestimate the prevalence of bowel and bladder symptoms in gynecologic cancer survivors. We sought to estimate the…”
Get full text

BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival by MARCHION, Douglas C, COTTRILL, Hope M, HAKAM, Ardeshir, LIHUA LI, DAN SU, MORENO, Carolina, JUDSON, Patricia L, BERCHUCK, Andrew, WENHAM, Robert M, ATE, Sachin M, GONZALEZ-BOSQUET, Jesus, BLOOM, Gregory C, YIN XIONG, ESCHRICH, Steven A, SEBTI, Said, CHEN, Dung-Tsa, LANCASTER, Johnathan M, NING CHEN, BICAKU, Elona, FULP, William J, BANSAL, Nisha, HYE SOOK CHON, STICKLES, Xiaomang B, KAMATH, Siddharth G

“…Despite initial sensitivity to chemotherapy, ovarian cancers (OVCA) often develop drug resistance, which limits patient survival. Using specimens and/or…”
Get full text